ITFI20020176A1 - SPECIFIC IMMUNOGLOBULIN FOR HUMAN TISSUE CALLICREIN, IMMUNOLOGICAL FORMULATION INCLUDING THE IMMUNOGLOBULIN AND RELATED DIAGNOSTIC KIT FOR THE DIAGNOSIS OF CEREBRAL ISCHEMIA. - Google Patents

SPECIFIC IMMUNOGLOBULIN FOR HUMAN TISSUE CALLICREIN, IMMUNOLOGICAL FORMULATION INCLUDING THE IMMUNOGLOBULIN AND RELATED DIAGNOSTIC KIT FOR THE DIAGNOSIS OF CEREBRAL ISCHEMIA.

Info

Publication number
ITFI20020176A1
ITFI20020176A1 ITFI20020176A ITFI20020176A1 IT FI20020176 A1 ITFI20020176 A1 IT FI20020176A1 IT FI20020176 A ITFI20020176 A IT FI20020176A IT FI20020176 A1 ITFI20020176 A1 IT FI20020176A1
Authority
IT
Italy
Prior art keywords
immunoglobulin
callicrein
diagnosis
human tissue
cerebral ischemia
Prior art date
Application number
Other languages
Italian (it)
Inventor
Julie Chao
Lee Chao
Costanza Emanueli
Paolo Madeddu
Paolo Porcu
Original Assignee
Angioprogen S R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angioprogen S R L filed Critical Angioprogen S R L
Priority to ITFI20020176 priority Critical patent/ITFI20020176A1/en
Priority to PCT/EP2003/010545 priority patent/WO2004029238A1/en
Priority to AU2003277885A priority patent/AU2003277885A1/en
Publication of ITFI20020176A1 publication Critical patent/ITFI20020176A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6445—Kallikreins (3.4.21.34; 3.4.21.35)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event
ITFI20020176 2002-09-24 2002-09-24 SPECIFIC IMMUNOGLOBULIN FOR HUMAN TISSUE CALLICREIN, IMMUNOLOGICAL FORMULATION INCLUDING THE IMMUNOGLOBULIN AND RELATED DIAGNOSTIC KIT FOR THE DIAGNOSIS OF CEREBRAL ISCHEMIA. ITFI20020176A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
ITFI20020176 ITFI20020176A1 (en) 2002-09-24 2002-09-24 SPECIFIC IMMUNOGLOBULIN FOR HUMAN TISSUE CALLICREIN, IMMUNOLOGICAL FORMULATION INCLUDING THE IMMUNOGLOBULIN AND RELATED DIAGNOSTIC KIT FOR THE DIAGNOSIS OF CEREBRAL ISCHEMIA.
PCT/EP2003/010545 WO2004029238A1 (en) 2002-09-24 2003-09-23 Human tissue kallikrein-specific immunoglobulin, immunologic formulation comprising the immunoglobulin and related diagnostic kit for the diagnosis of cerebral ischemia
AU2003277885A AU2003277885A1 (en) 2002-09-24 2003-09-23 Human tissue kallikrein-specific immunoglobulin, immunologic formulation comprising the immunoglobulin and related diagnostic kit for the diagnosis of cerebral ischemia

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITFI20020176 ITFI20020176A1 (en) 2002-09-24 2002-09-24 SPECIFIC IMMUNOGLOBULIN FOR HUMAN TISSUE CALLICREIN, IMMUNOLOGICAL FORMULATION INCLUDING THE IMMUNOGLOBULIN AND RELATED DIAGNOSTIC KIT FOR THE DIAGNOSIS OF CEREBRAL ISCHEMIA.

Publications (1)

Publication Number Publication Date
ITFI20020176A1 true ITFI20020176A1 (en) 2004-03-25

Family

ID=32040251

Family Applications (1)

Application Number Title Priority Date Filing Date
ITFI20020176 ITFI20020176A1 (en) 2002-09-24 2002-09-24 SPECIFIC IMMUNOGLOBULIN FOR HUMAN TISSUE CALLICREIN, IMMUNOLOGICAL FORMULATION INCLUDING THE IMMUNOGLOBULIN AND RELATED DIAGNOSTIC KIT FOR THE DIAGNOSIS OF CEREBRAL ISCHEMIA.

Country Status (3)

Country Link
AU (1) AU2003277885A1 (en)
IT (1) ITFI20020176A1 (en)
WO (1) WO2004029238A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2575791A1 (en) 2004-08-03 2006-02-16 Dyax Corp. Hk1-binding proteins
US20130315891A1 (en) 2012-05-25 2013-11-28 Matthew Charles Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
SI2854841T1 (en) 2012-06-04 2017-06-30 Diamedica Inc. Human tissue kallikrein 1 glycosylation isoforms
WO2018165551A1 (en) 2017-03-09 2018-09-13 Diamedica Inc. Dosage forms of tissue kallikrein 1

Also Published As

Publication number Publication date
WO2004029238A1 (en) 2004-04-08
AU2003277885A1 (en) 2004-04-19

Similar Documents

Publication Publication Date Title
LTC1620113I2 (en) Ivermectin topical composition for the treatment of dermatological diseases
AU2003265831A8 (en) Hyperspectral imaging of the human retina
DE60038252D1 (en) HUMAN ANTIBODY AGAINST GANGLIOSID GD3 FOR THE TRANSPLANT COMPLETIONARITY DETERMINE REGION AND DERIVATIVES OF THE ANTIBODY AGAINST THE GANGLIOSID GD3
EP2292649A3 (en) Therapeutic epitopes and uses thereof
WO2003057006A3 (en) Use of antibodies against the muc18 antigen
WO2005074985A3 (en) Methods of modulating cd200 and cd200r
DE60220719D1 (en) ANTIBODIES TO THE MUC18 ANTIGEN
WO2003096990A3 (en) Protein cages for the delivery of medical imaging and therapy
PT1446122E (en) USE OF FLIBANSERIN IN THE TREATMENT OF DISORDERS OF SEXUAL DESIRE
AU2003295644A1 (en) Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids and therapeutic uses therefor
BR0110748A (en) Multifunctional Nanodevice Platform
WO2003057837A3 (en) Methods for using anti-muc18 antibodies
WO2004033481A3 (en) Igf-binding protein-derived peptide or small molecule
WO2003025121A3 (en) Igf-binding protein-derived peptide or small molecule
FR2867684B1 (en) CREAM GEL CONTAINING IVERMECTIN
AU2002257703A1 (en) Use of cytokines of the tgf-beta superfamily for the treatment and diagnosis of skin related disorders
IL163547A0 (en) Use of the axl receptor for diagnosis and treatment of renal disease
WO2004025303A3 (en) Isoprostanes as markers of psychological stress in humans
EA200400399A1 (en) METHODS OF TREATMENT OF PULMONARY DISEASES
ITFI20020176A1 (en) SPECIFIC IMMUNOGLOBULIN FOR HUMAN TISSUE CALLICREIN, IMMUNOLOGICAL FORMULATION INCLUDING THE IMMUNOGLOBULIN AND RELATED DIAGNOSTIC KIT FOR THE DIAGNOSIS OF CEREBRAL ISCHEMIA.
WO2004081199A3 (en) Novel compositions and methods for the treatment of immune related disease
AU2003210266A8 (en) Treatment, diagnosis and imaging of disease
BR0110512A (en) Preparation to measure gastric emptying rate
FR2857597B1 (en) USE OF PEPTIDE CONJUGATES FOR THE PREPARATION OF COMPOSITIONS FOR THE PREVENTIVE AND CURATIVE TREATMENT OF ALOPECIA.
WO2003000733A3 (en) Glycopeptides, their preparation and use in the diagnosis or therapeutic treatment of multiple sclerosis